Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
clinical trials
life sciences
national blog main
boston
new york blog main
san francisco blog main
abbvie
advertising
agios pharmaceuticals
allergan
alzheimer's disease
archive
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
bluebird bio
cancer
cancer drugs
crispr
cynthia collins
david e. shaw
deals
drug discovery
duchenne muscular dystrophy
dyne therapeutics
editas medicine
enasidenib
facioscapulohumeral muscular dystrophy
fda
gene editing
gene therapy
google
healthcare
internet
investing
ipo
What
experimental
4
×
medicines
4
×
genetic
ipo
abbvie
ad
ads
advertising
ago
alliance
announced
bans
biotech
biotechs
company’s
considering
course
data
development
discover
diseases
drug
dyne
early
editas
editing
exits
expected
eyes
gene
google
growing
handiwork
having
healthcare
helped
humans
internal
ipos
landscape
Language
unset
Current search:
experimental
×
medicines
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
4 years ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
@slashgear.com
4 years ago
Google bans ad sales for unproven medical treatments
